Get the Stockscreener App
2.57
3.75%
-0.10
Edesa Biotech Inc stock is traded at $2.57, with a volume of 64,029.
It is down -3.75% in the last 24 hours and down -33.59% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
See More
Previous Close:
$2.67
Open:
$2.68
24h Volume:
64,029
Relative Volume:
1.17
Market Cap:
$24.78M
Revenue:
$328.80K
Net Income/Loss:
$-10.44M
P/E Ratio:
-1.9171
EPS:
-1.3406
Net Cash Flow:
$-7.72M
1W Performance:
-26.78%
1M Performance:
-33.59%
6M Performance:
-50.00%
1Y Performance:
+4.47%
1-Day Range:
$2.52
$2.7656
1-Week Range:
$2.52
$3.56
52-Week Range:
$0.72
$20.32
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
2.57 | 24.78M | 328.80K | -10.44M | -7.72M | -1.3406 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Edesa Biotech Inc Stock (EDSA) Latest News
Edesa Biotech completes US$3.5 million private placement - fasken.com
Edesa Biotech Stock Price Forecast. Should You Buy EDSA? - StockInvest.us
Stonepine Capital Management, LLC Expands Edesa Biotech Inc (EDS - GuruFocus
Insider share moves at Edesa Biotech (EDSA) detailed in new SEC filing - Stock Titan
Velan Capital Investment Management LP Expands Edesa Biotech Inc (EDSA) Stake - GuruFocus
Edesa Biotech (EDSA) Dips 3.5% as Shares Test Key Support ZoneDay Trade Opportunities - dars.gov.et
EDSA Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued Clinical-Stage InvestmentEPS Revision Trend - vinanet.vn
Stonepine group discloses sub-10% Edesa Biotech (NASDAQ: EDSA) position - Stock Titan
Velan Capital lifts Edesa Biotech (EDSA) stake to 9.99% with warrant leverage - Stock Titan
Edesa Biotech (NASDAQ: EDSA) major holder's multi-million-share stake detailed - stocktitan.net
EDSA: Recruitment in Phase 2 Vitiligo Study Set to Get Underway - finance.yahoo.com
Edesa Biotech completes US$25 million public offering - fasken.com
Edesa (EDSA) Results Review: The Bottom-Line Figure Trails Its Comparison at the Close; Price Reaction: Shares Close 17.22% Lower in Latest TradingInterim Report - vinanet.vn
Edesa Biotech Enters Underwriting Deal With Guggenheim for $23.1M Equity Offering - TradingView
Edesa Biotech Prices $25 Million Stock-and-Warrant Offering to Fund Drug Pipeline - finance.biggo.com
Edesa Biotech Shares Tumble 13% on $25 Million Equity Offering - finance.biggo.com
Edesa (EDSA) Quarter in Focus: EPS Does Not Reach the Reported Estimate for the Current Session; Share Move - vinanet.vn
Edesa Biotech Stock Sinks After Fresh Capital Raise - TradingView
Edesa Biotech raises USD 25m to fuel vitiligo Phase II - AllSci
Edesa Biotech Stock Sinks After Fresh Capital Raise - Yahoo Finance
Edesa (EDSA) Results Review: The Bottom-Line Figure Trails Its Comparison at the Close; Price Reaction: Shares Close 17.22% Lower in Latest TradingEstimate Revision Count - careplusvn.com
Edesa (EDSA) Results Review: The Bottom-Line Figure Trails Its Comparison at the Close; Price Reaction: Shares Close 17.22% Lower in Latest TradingQuarterly Profit Report - dars.gov.et
Edesa (EDSA) Quarter in Focus: EPS Does Not Reach the Reported Estimate for the Current Session; Share Move - careplusvn.com
Edesa (EDSA) Results Review: The Bottom-Line Figure Trails Its Comparison at the Close; Price Reaction: Shares Close 17.22% Lower in Latest TradingReturn On Assets - dars.gov.et
Edesa (EDSA) Results Review: The Bottom-Line Figure Trails Its Comparison at the Close; Price Reaction: Shares Close 17.22% Lower in Latest TradingFree Cash Flow Trends - dars.gov.et
Edesa (EDSA) Results Review: The Bottom-Line Figure Trails Its Comparison at the Close; Price Reaction: Shares Close 17.22% Lower in Latest TradingProfit Guidance Range - dars.gov.et
Edesa Biotech Raises $25 Million in Public Offering to Advance Immuno-Inflammatory Pipeline - TipRanks
Edesa Biotech prices $25M public offering at $5.50 per share By Investing.com - Investing.com Australia
Edesa Biotech prices $25M public offering at $5.50 per share - Investing.com Australia
Edesa Biotech prices $25M public offering at $5.50 per share - Investing.com Nigeria
Edesa Biotech prices $25M public offering at $5.50 per share - Investing.com South Africa
Edesa Biotech prices $25M public offering at $5.50 per share - Investing.com
Edesa Biotech prices $25M public offering at $5.50 per share - Investing.com Canada
Edesa Biotech Announces Pricing of $25.0 Million Public Offering - Yahoo Finance
Edesa Biotech stock tumbles on public offering launch By Investing.com - Investing.com Canada
Edesa Biotech Launches Public Offering of Common Shares, Warrants - marketscreener.com
Edesa Biotech Launches Public Offering to Fund Immuno-Inflammatory Pipeline - tipranks.com
Edesa Biotech stock tumbles on public offering launch By Investing.com - Investing.com South Africa
Edesa Biotech stock tumbles on public offering launch By Investing.com - Investing.com Nigeria
Edesa Biotech launches public offering of common shares - Investing.com
Edesa Biotech stock tumbles on public offering launch By Investing.com - Investing.com South Africa
Edesa Biotech stock tumbles on public offering launch By Investing.com - Investing.com Australia
Edesa Biotech launches public offering of common shares By Investing.com - Investing.com India
Edesa Biotech stock tumbles on public offering launch - Investing.com
Edesa Biotech stock tumbles on public offering launch By Investing.com - Investing.com UK
Edesa Biotech Announces Proposed Public Offering of Common Shares and Warrants - Quiver Quantitative
Edesa Biotech Announces Proposed Public Offering - The Manila Times
Edesa Biotech Announces Proposed Public Offering - Yahoo Finance
Edesa Biotech(EDSA) Stock Options Chain | Quotes & News - Moomoo
Edesa Biotech Announces Proposed Public Offering - GlobeNewswire
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edesa Biotech Inc Stock (EDSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nijhawan Pardeep | Chief Executive Officer |
Mar 10 '26 |
Buy |
6.60 |
1,000 |
6,599 |
628,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 05 '26 |
Buy |
3.90 |
10,000 |
39,000 |
402,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 04 '26 |
Buy |
4.26 |
10,000 |
42,560 |
392,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 03 '26 |
Buy |
3.63 |
10,000 |
36,300 |
382,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.00 |
2,000 |
4,000 |
627,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.28 |
1,000 |
2,280 |
372,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 27 '26 |
Buy |
2.22 |
30,000 |
66,696 |
371,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 26 '26 |
Buy |
1.58 |
20,571 |
32,480 |
615,797 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):